Champions Oncology, Inc. (CSBR:NASDAQ) closed at $4.72 on October 23, 2026, down 0.84% on the day. The stock trades 43.2% below its 52-week high of $8.31 and 2.8% above its 52-week low of $4.59. Over the past year, it lost 31.5%. Champions Oncology, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since October 23, 2025, CSBR closed higher on 104 days (41%). Its best day was December 15, 2025 (+16.07%) and its worst was December 16, 2025 (-13.72%). The stock moved 10% or more in a single session 5 times. It opened at least 5% above the previous day's high 3 times.
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. It also offers POS products, including personalized tumor boards that are designed to provide access to oncologists with expertise in particular tumor types; and provides access to gene sequencing that analyzes the genetic makeup of patient's tumor for the purpose of identifying useful drugs. In addition, the company offers Translational Oncology Solutions (TOS), including a preclinical Tumorgraft platform to pharmaceutical and biotechnology companies that use vivo studies, which rely on implanting multiple tumors from TumorBank in mice and testing the therapy of interest on tumors. Further, it pr...
Find more stocks like CSBR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.